Cleave Therapeutics, Inc.

Cleave Therapeutics, Inc. is a biotechnology company focused on developing innovative therapeutics to enhance cancer treatment, particularly in biomarker-driven therapies and personalized medicine. Cleave Therapeutics, Inc. was founded in 2011 and is headquartered in San Francisco, US.

The company specializes in advancing therapeutic solutions for cancer by leveraging biomarker-driven strategies. Founded by Peter Thompson, the company has completed 6 distinct funding deals, with the most recent fundraising event being a Series B round, which took place on June 4, 2019, raising USD 11. 97 mn. The total amount raised by the company now stands at USD 11.

97 mn with a current valuation of USD 35. 66 mn. Cleave Therapeutics, Inc. is dedicated to developing targeted cancer therapies through a focus on biomarker identification and personalized treatment strategies.

Their approach aims to create effective therapeutic options tailored to the specific genetic profiles of cancer patients, enhancing treatment efficacy and minimizing side effects. By integrating advanced medicinal chemistry and biological research, the company targets various cancers with unique therapeutic modalities designed to address unmet medical needs. The company's revenue is generated through partnerships and collaborations with research institutions and pharmaceutical companies involved in the development of cancer therapies. Their business model includes revenue from licensing agreements and collaborative research funding, enabling them to maintain a steady income stream as they advance their therapeutic candidates through clinical development.

Cleave Therapeutics, Inc. plans to utilize the recently raised Series B funding of USD 11. 97 mn to further develop its pipeline of biomarker-driven cancer therapies. This includes the introduction of new therapeutic candidates specifically targeting key market segments in oncology, with anticipated launches in the next 24 months.

The company is also eyeing expansion into European and Asian markets by late 2021, aiming to establish strategic collaborations with international pharmaceutical partners to enhance the reach of its innovative cancer treatments.